Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 589471, 11 pages
http://dx.doi.org/10.1155/2015/589471
Research Article

Blood or Urine IP-10 Cannot Discriminate between Active Tuberculosis and Respiratory Diseases Different from Tuberculosis in Children

1Translational Research Unit, Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases (INMI), 00149 Rome, Italy
2Italian Association for Solidarity among People (AISPO), P.O. Box 7146, Kampala, Uganda
3St. Francis Nsambya Hospital, P.O. Box 7146, Kampala, Uganda
4Swiss Tropical and Public Health Institute, Medical Services and Diagnostic Department, 4002 Basel, Switzerland
5University of Basel, 4003 Basel, Switzerland
6Ifakara Health Institute, Bagamoyo Research and Training Center, P.O. Box 78373, Bagamoyo, Tanzania
7Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases (INMI), 00149 Rome, Italy

Received 13 May 2015; Revised 8 July 2015; Accepted 14 July 2015

Academic Editor: Subash Babu

Copyright © 2015 Linda Petrone et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. WHO, “Global tuberculosis report 2014,” WHO Global TB Report 2014, 2014. View at Google Scholar
  2. D. Portevin, F. Moukambi, P. Clowes et al., “Assessment of the novel T-cell activation marker-tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study,” The Lancet Infectious Diseases, vol. 14, no. 10, pp. 931–938, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. H. J. Zar, T. G. Connell, and M. Nicol, “Diagnosis of pulmonary tuberculosis in children: new advances,” Expert Review of Anti-Infective Therapy, vol. 8, no. 3, pp. 277–288, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. L. E. Cuevas, R. Browning, P. Bossuyt et al., “Evaluation of tuberculosis diagnostics in children: 2. Methodological issues for conducting and reporting research evaluations of tuberculosis diagnostics for intrathoracic tuberculosis in children. Consensus from an expert panel,” The Journal of Infectious Diseases, vol. 205, supplement 2, pp. S209–S215, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Berti, L. Galli, E. Venturini, M. de Martini, and E. Chiappini, “Tuberculosis in childhood: a systematic review of national and international guidelines,” BMC Infectious Diseases, vol. 14, supplement 1, article S3, 2014. View at Google Scholar · View at Scopus
  6. National Institute for Health and Care Excellence, Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control, 2011.
  7. J. R. Groom and A. D. Luster, “CXCR3 ligands: redundant, collaborative and antagonistic functions,” Immunology & Cell Biology, vol. 89, no. 2, pp. 207–215, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Sauty, M. Dziejman, R. A. Taha et al., “The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells,” The Journal of Immunology, vol. 162, no. 6, pp. 3549–3558, 1999. View at Google Scholar · View at Scopus
  9. E. Ferrero, P. Biswas, K. Vettoretto et al., “Macrophages exposed to Mycobacterium tuberculosis release chemokines able to recruit selected leucocyte subpopulations: focus on γδ cells,” Immunology, vol. 108, no. 3, pp. 365–374, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. N. N. Chegou, A. K. Detjen, L. Thiart et al., “Utility of host markers detected in quantiferon supernatants for the diagnosis of tuberculosis in children in a high-burden setting,” PLoS ONE, vol. 8, no. 5, Article ID e64226, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Lighter, M. Rigaud, M. Huie, C.-H. Peng, and H. Pollack, “Chemokine IP-10: an adjunct marker for latent tuberculosis infection in children,” International Journal of Tuberculosis and Lung Disease, vol. 13, no. 6, pp. 731–736, 2009. View at Google Scholar · View at Scopus
  12. E. Whittaker, A. Gordon, and B. Kampmann, “Is IP-10 a better biomarker for active and latent tuberculosis in children than IFNgamma?” PLoS ONE, vol. 3, no. 12, Article ID e3901, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Azzurri, O. Y. Sow, A. Amedei et al., “IFN-γ-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection,” Microbes and Infection, vol. 7, no. 1, pp. 1–8, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Ruhwald, J. Petersen, K. Kofoed et al., “Improving T-cell assays for the diagnosis of latent TB infection: potential of a diagnostic test based on IP-10,” PLoS ONE, vol. 3, no. 8, Article ID e2858, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Goletti, A. Sanduzzi, and G. Delogu, “Performance of the tuberculin skin test and interferon-g release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches,” The Journal of Rheumatology, vol. 41, no. 91, pp. 24–31, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. B. S. A. Kabeer, A. Raja, B. Raman et al., “IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy,” BMC Infectious Diseases, vol. 11, article 135, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Cannas, L. Calvo, T. Chiacchio et al., “IP-10 detection in urine is associated with lung diseases,” BMC Infectious Diseases, vol. 10, article 333, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. WHO, Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children, World Health Organization, Geneva, Switzerland, 2014.
  19. C. A. Wright, A. C. Hesseling, C. Bamford, S. M. Burgess, R. Warren, and B. J. Marais, “Fine-needle aspiration biopsy: a first-line diagnostic procedure in paediatric tuberculosis suspects with peripheral lymphadenopathy?” The International Journal of Tuberculosis and Lung Disease, vol. 13, no. 11, pp. 1373–1379, 2009. View at Google Scholar · View at Scopus
  20. V. Vanini, E. Petruccioli, C. Gioia et al., “IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country,” Journal of Infection, vol. 65, no. 1, pp. 49–59, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Petrone, T. Chiacchio, V. Vanini et al., “High urine IP-10 levels associate with chronic HCV infection,” Journal of Infection, vol. 68, no. 6, pp. 591–600, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Maartens, C. Celum, and S. R. Lewin, “HIV infection: epidemiology, pathogenesis, treatment, and prevention,” The Lancet, vol. 384, no. 9939, pp. 258–271, 2014. View at Publisher · View at Google Scholar
  23. M. Muenchhoff, A. J. Prendergast, and P. J. R. Goulder, “Immunity to HIV in early life,” Frontiers in Immunology, vol. 5, article 391, 2014. View at Publisher · View at Google Scholar
  24. M. Liu, S. Guo, J. M. Hibbert et al., “CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications,” Cytokine and Growth Factor Reviews, vol. 22, no. 3, pp. 121–130, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. L. A. Ramirez, T. A. Arango, E. Thompson, M. Naji, P. Tebas, and J. D. Boyer, “High IP-10 levels decrease T cell function in HIV-1-infected individuals on ART,” Journal of Leukocyte Biology, vol. 96, no. 6, pp. 1055–1063, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Casrouge, J. Decalf, M. Ahloulay et al., “Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV,” The Journal of Clinical Investigation, vol. 121, no. 1, pp. 308–317, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Sollai, L. Galli, M. de Martino, and E. Chiappini, “Systematic review and meta-analysis on the utility of Interferon-gamma release assays for the diagnosis of Mycobacterium tuberculosis infection in children: a 2013 update,” BMC Infectious Diseases, vol. 14, supplement 1, article S6, 2014. View at Publisher · View at Google Scholar
  28. M. Sester, F. van Leth, J. Bruchfeld et al., “Risk assessment of tuberculosis in immunocompromised patients. A TBNET study,” The American Journal of Respiratory and Critical Care Medicine, vol. 190, no. 10, pp. 1168–1176, 2014. View at Publisher · View at Google Scholar
  29. D. Goletti, S. Carrara, H. Mayanja-Kizza et al., “Response to M. tuberculosis selected RD1 peptides in ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study,” BMC Infectious Diseases, vol. 8, article 11, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. P. H. Lagrange, S. K. Thangaraj, R. Dayal et al., “A toolbox for tuberculosis (TB) diagnosis: an Indian multicentric study (2006–2008). Evaluation of QuantiFERON-TB gold in tube for TB diagnosis,” PLoS ONE, vol. 8, no. 9, Article ID e73579, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Xia, X. Wang, F. Li et al., “Diagnostic values of the QuantiFERON-TB Gold In-tube assay carried out in China for diagnosing pulmonary tuberculosis,” PLOS ONE, vol. 10, no. 4, Article ID e0121021, 2015. View at Publisher · View at Google Scholar